{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-016300","form_type":"8-K","ticker":"KYNB","cik":"0000921299","company_name":"KYNTRA BIO, INC.","filed_at":"2023-05-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:42.821012+00:00","generated_at":"2026-06-16T05:57:21.636104+00:00","sec_items":["1.01","2.03"],"event_type":"debt","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"FibroGen enters $75M senior secured term loan with Morgan Stanley Tactical Value; up to $150M total","bullets":["Initial $75M term loan funded by May 8, 2023; additional $37.5M milestone-based loan and $37.5M discretionary loan available.","Interest rate 14.0% per annum payable monthly; maturity May 8, 2026; no amortization payments.","Minimum $30M unrestricted cash and cash equivalents covenant tested monthly.","Loans secured by substantially all assets; guarantees from subsidiaries excluding Chinese subsidiary.","Prepayment requires make-whole amount including remaining scheduled interest to maturity."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-016300","json":"https://secwatch.observer/filing/0000950170-23-016300.json","markdown":"https://secwatch.observer/filing/0000950170-23-016300.md","text":"https://secwatch.observer/filing/0000950170-23-016300.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/921299/000095017023016300/0000950170-23-016300-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/921299/000095017023016300/fgen-20230429.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T05:57:21.636104+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"dbf9fd8a84dce20ea620dedf68a96f06bad73d9a","claim":"KYNTRA BIO, INC. entered into Financing Agreement with investment funds managed by Morgan Stanley Tactical Value valued at $75,000,000 initial term loan, $37,500,000 delayed draw term loan (effective 2023-04-29).","evidence_excerpt":"On April 29, 2023 (the “ Signing Date ”), FibroGen, Inc. (the “ Company ”) entered into a financing agreement (“ Financing Agreement ”) with investment funds managed by Morgan Stanley Tactical Value, as lenders (the “ Lenders ”), and Wilmington Trust, National Association, as the administrative agent (the “ Administrative Agent ”), providing for senior secured term loan facilities consisting of (i) a $75,000,000 initial term loan (the “ Initial Term Loan ”), (ii) a $37,500,000 delayed draw term loan that will be funded upon the achievement of certain clinical development milestones (“ Delayed Draw Term Loan 1 ”) and, (iii) an uncommitted delayed draw term loan of up to $37,500,000, to be funded at the Lenders sole discretion, (“ Delayed Draw Term Loan 2 ” and, together with the Initial Term Loan and Delayed Draw Term Loan 1, the “ Term Loans ”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/921299/000095017023016300/0000950170-23-016300-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"credit facility"},{"label":"Counterparty","value":"investment funds managed by Morgan Stanley Tactical Value"},{"label":"Value","value":"$75,000,000 initial term loan, $37,500,000 delayed draw term loan"},{"label":"Effective","value":"2023-04-29"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}